ATE266415T1 - Behandlung von dilatierte kardiomyopathie durch entfernung von autoantikoerpern - Google Patents

Behandlung von dilatierte kardiomyopathie durch entfernung von autoantikoerpern

Info

Publication number
ATE266415T1
ATE266415T1 AT96941378T AT96941378T ATE266415T1 AT E266415 T1 ATE266415 T1 AT E266415T1 AT 96941378 T AT96941378 T AT 96941378T AT 96941378 T AT96941378 T AT 96941378T AT E266415 T1 ATE266415 T1 AT E266415T1
Authority
AT
Austria
Prior art keywords
patient
treatment
column
immunoapheresis
pressure
Prior art date
Application number
AT96941378T
Other languages
English (en)
Inventor
Petra Reinke
Stefan Brehme
Gert Baumann
Robert Koll
Jutta Mueller-Derlich
Stephan Felix
Reiner Spaethe
Original Assignee
Edwards Lifesciences Corp
Petra Reinke
Stefan Brehme
Gert Baumann
Stephan Felix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24232937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE266415(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Edwards Lifesciences Corp, Petra Reinke, Stefan Brehme, Gert Baumann, Stephan Felix filed Critical Edwards Lifesciences Corp
Application granted granted Critical
Publication of ATE266415T1 publication Critical patent/ATE266415T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physical Water Treatments (AREA)
  • Developing Agents For Electrophotography (AREA)
AT96941378T 1995-11-15 1996-11-15 Behandlung von dilatierte kardiomyopathie durch entfernung von autoantikoerpern ATE266415T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55926295A 1995-11-15 1995-11-15
PCT/US1996/018457 WO1997017980A1 (en) 1995-11-15 1996-11-15 Treatment of cardiomyopathy by removal of autoantibodies

Publications (1)

Publication Number Publication Date
ATE266415T1 true ATE266415T1 (de) 2004-05-15

Family

ID=24232937

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96941378T ATE266415T1 (de) 1995-11-15 1996-11-15 Behandlung von dilatierte kardiomyopathie durch entfernung von autoantikoerpern

Country Status (7)

Country Link
US (1) US7022322B2 (de)
EP (1) EP0862444B2 (de)
JP (1) JP2002504831A (de)
AT (1) ATE266415T1 (de)
AU (1) AU731452B2 (de)
DE (1) DE69632476T3 (de)
WO (1) WO1997017980A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8197430B1 (en) * 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US6406861B1 (en) 1998-10-07 2002-06-18 Cell Genesys, Inc. Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration
US6464976B1 (en) * 1999-09-07 2002-10-15 Canji, Inc. Methods and compositions for reducing immune response
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
US8609436B2 (en) 2000-03-17 2013-12-17 Guy's & St Thomas' Hospital NHS Trust (“GST”) Method
US8088586B2 (en) * 2000-03-17 2012-01-03 Oxford Radcliffe Hospital Nhs Trust Method of producing a body fluid sample depleted of anti-MHC antibodies
JP4541490B2 (ja) * 2000-04-07 2010-09-08 株式会社カネカ 拡張型心筋症用吸着体
AU2002355846A1 (en) 2001-08-01 2003-02-17 Anil K. Chauhan Immune complexes
PL1949915T3 (pl) * 2004-04-30 2013-04-30 Biopheresis Tech Inc Sposób i układ do usuwania rozpuszczalnych TNFR1, TNFR2 i IL2R u pacjentów
US8034785B2 (en) 2004-10-28 2011-10-11 Kaneka Corporation Adsorbent adsorbing antibody against β1 adrenoreceptor
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
EP1832600A1 (de) * 2006-03-09 2007-09-12 Max-Delbrück-Centrum Für Molekulare Medizin Peptide gegen Autoantikörper verbunden mit Glaukom und deren Verwendung
DE102006042012A1 (de) * 2006-09-07 2008-03-27 Fresenius Medical Care Deutschland Gmbh Verfahren zur Unterstützung von Immuntherapien
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals
JPWO2008099855A1 (ja) * 2007-02-14 2010-05-27 旭化成クラレメディカル株式会社 自己抗体吸着材
US8420330B2 (en) * 2011-07-15 2013-04-16 Myra A. Lipes Diagnosis and treatment of cardiac troponin 1 (cTn1) autoantibody-mediated heart disease
US7601689B2 (en) * 2007-04-12 2009-10-13 Naidu Lp Angiogenin complexes (ANGex) and uses thereof
US8834887B2 (en) 2007-09-26 2014-09-16 National Cerebral And Cardiovascular Center Drug for suppressing pathogen occurring in vivo
EP2110140A1 (de) * 2008-04-18 2009-10-21 Gert Baumann Behandlung von Thromboangiitis obliterans mittels Autoantikörperentfernung
KR20100041277A (ko) * 2008-10-13 2010-04-22 재단법인서울대학교산학협력재단 응집핵이 결합된 고분자 지지체
EP4218559A1 (de) 2014-02-25 2023-08-02 ICU Medical, Inc. Patientenuberwachungssystem mit gatekeeper-signal und entsprechendes verfahren
CA3002372C (en) 2015-10-19 2021-03-02 Icu Medical, Inc. Hemodynamic monitoring system with detachable display unit
EP3607978A1 (de) * 2018-08-06 2020-02-12 Pentracor GmbH Vereinfachte regeneration von apheresesäulen
EP4185598A4 (de) * 2020-07-22 2024-10-09 The Rockefeller Univ Typ-1-ifn-assays und verfahren zur diagnose der anfälligkeit für und behandlung von viruserkrankungen sowie virusimpfstoffe mit covid-19

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223672A (en) * 1979-02-08 1980-09-23 Baxter Travenol Laboratories, Inc. Variable volume plasma treatment chamber for an apparatus for the extracorporeal treatment of disease
US4681870A (en) * 1985-01-11 1987-07-21 Imre Corporation Protein A-silica immunoadsorbent and process for its production
WO1991017171A1 (en) * 1990-05-07 1991-11-14 Oklahoma Medical Research Foundation NUCLEOTIDE SEQUENCE ENCODING A 52 kDa Ro/SSA AUTOANTIGEN
CA2103159A1 (en) * 1991-05-15 1992-11-16 Ake Lernmark Cloning and expression of human islet glutamic acid decarboxylase autoantigen
US5295953A (en) * 1992-05-26 1994-03-22 Hemagen/Pfc Method and apparatus for extracorporeal separation of fluorochemicals from whole blood of a patient
EP0804734B1 (de) * 1994-05-13 2005-05-04 Miltenyi Biotec GmbH An protein gebundene sterile und pyrogenfreie säulen zum binden und entfernen von substanzen aus blut

Also Published As

Publication number Publication date
US20030125657A1 (en) 2003-07-03
JP2002504831A (ja) 2002-02-12
EP0862444B1 (de) 2004-05-12
WO1997017980A1 (en) 1997-05-22
AU1054097A (en) 1997-06-05
US7022322B2 (en) 2006-04-04
DE69632476T2 (de) 2005-05-12
DE69632476D1 (de) 2004-06-17
EP0862444B2 (de) 2014-04-09
DE69632476T3 (de) 2014-05-22
EP0862444A1 (de) 1998-09-09
AU731452B2 (en) 2001-03-29

Similar Documents

Publication Publication Date Title
ATE266415T1 (de) Behandlung von dilatierte kardiomyopathie durch entfernung von autoantikoerpern
FR17C1062I2 (fr) Anticorps specifiques a l' humain cd22 et leurs utilisation therapeutiques et diagnostiques
ATE419014T1 (de) Verbindungen zur behandlung der ischaemischen gewebe
FR2703693B1 (fr) Procédé rapide de détermination d'une séquence d'ADN et application au séquençage et au diagnostic.
ATE482234T1 (de) Antikörper gegen kdr, deren herstellung und verwendungen
EA200001169A1 (ru) Специфично связывающиеся молекулы для сцинтиграфии, содержащие их конъюгаты и терапевтический способ лечения ангиогенеза
DE69034261D1 (de) Antikörper gegen VLA-4
MY136603A (en) Biological products
DE69535133D1 (de) Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4
NO982062D0 (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
EP1064403A4 (de) Antisense modulation von pecam-1
DK43890D0 (da) Nucleinsyre, vektorer og celler indeholdende den, derudfra fremstillede produkter og disses anvendelse
DE69129460D1 (de) Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
RU2004126238A (ru) Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro
DE60125563D1 (de) Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten
DE3584872D1 (de) Verfahren zur herstellung von monoklonalen antikoerpern gegen hbsag.
BR9603826A (pt) Processo para recuperar imunoglobulina de frações produzidas durante o fracionamento de plasma sanguíneo humano
ATE191502T1 (de) Corticotropinauslösefaktor-bindendes protein
DE59508509D1 (de) Dna-expressionsvektoren zur verwendung in der gentherapeutischen behandlung von gefässerkrankungen
CA2236598A1 (en) Treatment of cardiomyopathy by removal of autoantibodies
DE3786673D1 (de) Verfahren zur entfernung unerwuenschter zellen aus menschlichen lymphozytenpopulationen, anwendung des verfahrens zur herstellung monoklonaler antikoerper und dafuer geeigneter kit.
DE69929683D1 (de) Antisense modulierung von lfa-3
Honoré et al. Nucleotide sequence of cDNA covering the complete coding part of the human vimentin gene.
WO2001032693A3 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
DE69232140D1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties